Search
Grace Therapeutics, Inc
GRCEAdd to Watchlist
2.170USD
+0.010+0.46%
Market hours （ET）Quotes delayed by 15 min
35.31MMarket Cap
LossP/E TTM
More Details of Grace Therapeutics, Inc Company
Grace Therapeutics, Inc. is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, and reduced side effects. Its lead clinical asset, GTx-104, is an intravenous infusion targeting aneurysmal Subarachnoid Hemorrhage (aSAH), a rare and life-threatening medical emergency in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull. The nanoparticle technology of GTx-104 facilitates aqueous formulation of insoluble nimodipine for a standard peripheral IV infusion. Its other pipeline includes GTX-102, which is targeted as the first potential therapy for the treatment of ataxia-telangiectasia (AT) in a pediatric population and GTx-101, which is a topical administration via a bioadhesive, film-forming polymer, for the treatment of pain associated with postherpetic neuralgia.
Grace Therapeutics, Inc Profile
Ticker SymbolGRCE
Company nameGrace Therapeutics, Inc
IPO dateMar 07, 2013
CEOKohli (Prashant)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endMar 07
Address103 Carnegie Center
CityPRINCETON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code08540
Phone16093221602
Websitehttps://www.gracetx.com/
Ticker SymbolGRCE
IPO dateMar 07, 2013
CEOKohli (Prashant)
Company Executives of Grace Therapeutics, Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Mr. Amresh Kumar, Ph.D.
Mr. Amresh Kumar, Ph.D.
Vice President - Program Management
Vice President - Program Management
11.12K
--
Dr. R. Loch Macdonald, M.D., Ph.D.
Dr. R. Loch Macdonald, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. S. George Kottayil
Dr. S. George Kottayil
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Vimal Kavuru
Mr. Vimal Kavuru
Independent Chairman of the Board
Independent Chairman of the Board
426.32K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
37.90K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
Mr. Prashant Kohli
Mr. Prashant Kohli
Chief Executive Officer, Director
Chief Executive Officer, Director
21.36K
--
FAQs
Who are the top five shareholders of Grace Therapeutics, Inc?
The top five shareholders of Grace Therapeutics, Inc are: Mr. Vimal Kavuru
How many institutions hold shares of Grace Therapeutics, Inc (GRCE)?
As of 2026Q1, 43 institutions hold shares of Grace Therapeutics, Inc, with a combined market value of approximately 3.68M, accounting for 23.76% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -152471.00.